Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MindWalk Holdings's enterprise value is $61.07 Mil.
MindWalk Holdings's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-10.09 Mil. Therefore, MindWalk Holdings's EV-to-EBITDA for today is -6.05.
The historical rank and industry rank for MindWalk Holdings's EV-to-EBITDA or its related term are showing as below:
HYFT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -644.77 Med: -6.2 Max: 216.32
Current: -6.05
During the past 13 years, the highest EV-to-EBITDA of MindWalk Holdings was 216.32. The lowest was -644.77. And the median was -6.20.
HYFT's EV-to-EBITDA is ranked worse than 100% of 414
companies
in the Biotechnology industry
Industry Median: 13.54
vs HYFT: -6.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MindWalk Holdings's PE Ratio (TTM) for today is calculated as:
MindWalk Holdings's share price for today is $1.43.
MindWalk Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.217.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MindWalk Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MindWalk Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's EV-to-EBITDA falls into.
MindWalk Holdings's current Enterprise Value is $61.07 Mil.
MindWalk Holdings's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a EV-to-EBITDA of -6.05 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MindWalk Holdings. According to the industry distribution chart, MindWalk Holdings ranks #999999 out of 414 companies in the Biotechnology industry.
Is MindWalk Holdings' EV-to-EBITDA too high?
MindWalk Holdings' current EV-to-EBITDA is -6.05. Based on the distribution chart, MindWalk Holdings ranks #999999 out of 414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindWalk Holdings has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' EV-to-EBITDA compare to IMA and CING?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #999999 out of 414 companies for EV-to-EBITDA. This places MindWalk Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.54, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MindWalk Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindWalk Holdings's current EV-to-EBITDA is -6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.99, compared to a current price of $1.43 — trading 44.4% above its estimated fair value. The current EV-to-EBITDA is -6.05. MindWalk Holdings' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current EV-to-EBITDA is -6.05 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.43 is trading 44.4% above its estimated GF Value™ of $0.99.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
EV-to-EBITDA: -6.05
GF Value™: $0.99 vs. price of $1.43 (44.4% above fair value)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
45GF Score
Get the complete analysis for HYFT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
